CG Oncology, Inc. Files S-1 Registration Statement

TL;DR

<b>CG Oncology, Inc. has filed an S-1 registration statement, signaling its intent to offer securities to the public.</b>

AI Summary

CG Oncology, Inc. (CGON) filed a IPO Registration (S-1) with the SEC on January 2, 2024. CG Oncology, Inc. filed an S-1 registration statement with the SEC on January 2, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. Its principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618. The filing is for a registration of securities under the Securities Act of 1933. CG Oncology, Inc. is classified under SIC code 2836: Biological Products (No Diagnostic Substances).

Why It Matters

For investors and stakeholders tracking CG Oncology, Inc., this filing contains several important signals. This S-1 filing is a prerequisite for an Initial Public Offering (IPO), indicating CG Oncology's intention to raise capital and become a publicly traded company. The filing provides detailed information about the company's business, financial condition, and the securities it plans to offer, allowing potential investors to make informed decisions.

Risk Assessment

Risk Level: low — CG Oncology, Inc. shows low risk based on this filing. The filing is a standard S-1 registration statement, which is a preliminary step for an IPO and does not contain specific financial performance data or risk factors that would indicate a high-risk profile at this stage.

Analyst Insight

Monitor future filings for the prospectus, which will contain detailed financial information, risk factors, and the proposed offering price, to assess investment potential.

Key Numbers

• 2836 — SIC Code (Biological Products (No Diagnostic Substances))
• 371611499 — IRS Number (Employer Identification No.)
• 333-276350 — SEC File Number (Registration Statement)

Key Players & Entities

• CG Oncology, Inc. (company) — Registrant name
• Securities and Exchange Commission (regulator) — Filing recipient
• January 2, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618 (address) — Principal executive offices
• Arthur Kuan (person) — Chief Executive Officer
• Latham & Watkins LLP (company) — Legal counsel
• Cooley LLP (company) — Legal counsel

Forward-Looking Statements

• CG Oncology, Inc. will successfully complete its IPO. (CG Oncology, Inc.) — medium confidence, target: Q1 2024
• The company will use IPO proceeds to advance its biological product pipeline. (CG Oncology, Inc.) — high confidence, target: Q4 2024

FAQ

Industry Context

CG Oncology operates in the biotechnology sector, focusing on oncology treatments. The S-1 filing indicates a move towards public investment in this specialized area of healthcare.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1 filing for detailed business descriptions and risk factors.
2. Track subsequent SEC filings for the prospectus and IPO pricing.
3. Research the oncology and biotechnology market for competitive landscape analysis.

Key Dates

• 2024-01-02: S-1 Filing — Registration statement filed with the SEC.

Year-Over-Year Comparison

This is the initial S-1 filing, so there is no prior filing to compare against.

Key Financial Figures

• $9.9 billion — t has been forecast to be approximately $9.9 billion by 2028, according to Evaluate Pharma.

Filing Documents

• d551455ds1.htm (S-1) — 2248KB
• d551455dex31.htm (EX-3.1) — 140KB
• d551455dex32.htm (EX-3.2) — 124KB
• d551455dex33.htm (EX-3.3) — 37KB
• d551455dex34.htm (EX-3.4) — 177KB
• d551455dex42.htm (EX-4.2) — 263KB
• d551455dex101.htm (EX-10.1) — 200KB
• d551455dex102.htm (EX-10.2) — 301KB
• d551455dex103.htm (EX-10.3) — 229KB
• d551455dex104.htm (EX-10.4) — 97KB
• d551455dex105.htm (EX-10.5) — 17KB
• d551455dex106.htm (EX-10.6) — 126KB
• d551455dex107.htm (EX-10.7) — 491KB
• d551455dex108.htm (EX-10.8) — 22KB
• d551455dex109.htm (EX-10.9) — 82KB
• d551455dex1010.htm (EX-10.10) — 28KB
• d551455dex1011.htm (EX-10.11) — 25KB
• d551455dex1012.htm (EX-10.12) — 102KB
• d551455dex1013.htm (EX-10.13) — 110KB
• d551455dex1014.htm (EX-10.14) — 119KB
• d551455dex1015.htm (EX-10.15) — 126KB
• d551455dex1016.htm (EX-10.16) — 113KB
• d551455dex1017.htm (EX-10.17) — 119KB
• d551455dex231.htm (EX-23.1) — 1KB
• d551455dexfilingfees.htm (EX-FILING FEES) — 13KB
• g551455g03p01.jpg (GRAPHIC) — 55KB
• g551455g08o97.jpg (GRAPHIC) — 140KB
• g551455g12m13.jpg (GRAPHIC) — 144KB
• g551455g13p01.jpg (GRAPHIC) — 117KB
• g551455g15m15.jpg (GRAPHIC) — 265KB
• g551455g19a20.jpg (GRAPHIC) — 162KB
• g551455g22a22.jpg (GRAPHIC) — 34KB
• g551455g23a23.jpg (GRAPHIC) — 109KB
• g551455g24a25.jpg (GRAPHIC) — 124KB
• g551455g59q43.jpg (GRAPHIC) — 176KB
• g551455g78c79.jpg (GRAPHIC) — 63KB
• g551455g88j37.jpg (GRAPHIC) — 135KB
• g551455g89m10.jpg (GRAPHIC) — 113KB
• 0001193125-24-000766.txt (&nbsp;) — 7569KB

Risk Factors

Risk Factors 14 Special Note Regarding Forward-Looking Statements 75 Market and Industry Data 76

Use of Proceeds

Use of Proceeds 77 Dividend Policy 79 Capitalization 80

Managements Discussion and Analysis of Financial

Managements Discussion and Analysis of Financial Condition and Results of Operations 85

Business

Business 101 Management 133 Page Executive and Director Compensation 141 Certain Relationships and Related Person Transactions 160 Principal Stockholders 165

Description of Capital Stock

Description of Capital Stock 167 Shares Eligible For Future Sale 173 Material United States Federal Income Tax Consequences to Non-U.S. Holders 176

Underwriting

Underwriting 180 Legal Matters 189 Experts 189 Where You Can Find More Information 189 Index to Financial Statements F-1 Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus, or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should carefully read this entire prospectus, including the information in the sections title

View Full Filing

View this S-1 filing on SEC EDGAR